The RADAR-AD project has published two new papers this month. The first is an article published in the journal “Alzheimer’s and Therapy”, explaining the design of the RADAR-AD clinical study. The aim of the RADAR-AD study is to assess how well Remote Monitoring Technologies (RMTs) can measure impairment in activities of daily living in all stages of Alzheimer’s disease (AD).
Impairment in activities of daily living in AD is typically measured using standard clinical questionnaires. However, these questionnaires are only performed once in a while, and depend on someone’s memory. RMTs, such as smartphone applications, wearables and home-based sensors, can change these periodic assessments to more frequent or even continuous monitoring. Moreover, these RMTs do not rely on recall or do not need any action on the part of patients or caregivers at all, and therefore measure more objectively.
First complete results from the RADAR-AD study are expected to be published in 2022. Read the article, called “Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study”, here:
The second new article from the RADAR-AD consortium was published in the journal “Frontiers in Aging Neuroscience”. The article shows how people affected by Alzheimer’s disease (AD) can be involved in the design and implementation of dementia research studies, in particular in the selection of devices (wearables) to assess and monitor function in AD in a trial.
It includes members of the Patient Advisory Board (PAB) appointed for the RADAR-AD project, who have been involved in the project right from the start. The article can help other researchers involved in similar trials with the selection of devices and to understand some of the preferences, expectations and concerns of people affected by AD about remote assessment of their condition with wearables and devices.
As the conclusions reveal, the PAB highlighted some features expected by the researchers such as the importance of comfort and convenience but also others that might have otherwise been overlooked, such as feedback indications. Read the article, called “Wearable Devices for Assessing Function in Alzheimer’s Disease: A European Public Involvement Activity About the Features and Preferences of Patients and Caregivers”, here:
